Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden Lead program is AT-108, a first-in-class, off-the-shelf intra-tumoral therapy that leads to personalized and…